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INTRODUCTION
The human genome encodes approximately 518
kinases, including 90 tyrosine kinases (TK) and 43
tyrosine-like kinases [1]. Phosphorylated tyrosine serves
as a binding site for several signal transducers that initiate
multiple signaling pathways, resulting in cell proliferation,
migration, metastasis, resistance to apoptosis, and
angiogenesis [2]. Epidermal growth factor receptor
(EGFR) appears to play a central role in tumorigenesis,
and targeting this receptor may provide a unique
approach for treating EGFR-expressing cancers [3]. This
concept led to the development and regulatory approval of
small-molecule EGFR TK inhibitors (TKIs) such as
gefitinib and erlotinib; however, clinical trials have
revealed significant variability in the response to TKIs.
Good clinical responses have been observed most fre-
quently in women, nonsmokers, patients with adeno-
carcinomas, and patients of East Asian origin [4,5].
Activating mutations of EGFR have been reported in a
subset of patients with pulmonary adenocarcinomas,
and tumors with EGFR mutations are highly sensitive to
gefitinib [6,7]. Furthermore, the incidence of EGFR
mutations is higher in East Asians compared with
Caucasian patients and in those with adenocarcinoma [7]. 
Therefore, we investigated the presence of EGFR
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Background/Aims: Mutations of the epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral
oncogene (KRAS) are important in the pathogenesis of lung cancer, and recent reports have revealed racial and
geographical differences in mutation expression.
Methods: This study was conducted to investigate the prevalence of EGFR and KRAS mutations and their
correlation with clinical variables in Korean patients with adenocarcinoma of the lung. Formalin-fixed
adenocarcinoma specimens from 104 randomly selected patients diagnosed at Kosin University Gospel Hospital
from October 1996 to January 2005 were used for the study.
Results: We found a high prevalence of EGFR mutations and a low prevalence of KRAS mutations. EGFR
mutations were present in 24% (25 of 104) of the samples: one mutation in exon 18, 13 in exon 19, one in exon
20, and 10 in exon 21. The presence of an EGFR mutation was not associated with gender, smoking history,
histological grade, age, bronchioalveolar components, or cancer stage in patients with adenocarcinoma of the
lung.
Conclusions: Mutations of KRAS were present in 9.6% (9 of 94) of the samples: eight in codon 12 and one in
codon 13. EGFR mutations were never found in tumors with KRAS mutations, suggesting a mutually exclusive
relationship. (Korean J Intern Med 2009;24:48-54)
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adenocarcinoma of the lung, to determine the correlation
between clinical features and the presence of Kirsten rat
sarcoma viral oncogene (KRAS) mutations. 
METHODS
Patients
Primary tumor samples from patients with ade-
nocarcinoma of the lung were obtained from 104
randomly selected patients with lung cancer who were
diagnosed at Kosin University Gospel Hospital, Busan,
Korea from October 1996 to January 2005. Clinical
information, including gender, age at diagnosis, and
smoking history, were obtained by a retrospective review
of the medical history recorded in the patients’ charts. We
excluded patients with metastatic adenocarcinoma and
those who were treated with gefitinib, because treatment
with TKIs alters the prognosis of adenocarcinoma in East
Asian patients. The stage of the disease was the post-
operative pathological stage in patients who had
undergone surgery and the pretreated stage for non-
surgically treated patients.
Mutational analysis (DNA sequencing)
DNA was extracted from five paraffin-embedded
sections of 10-µM thickness representing a portion of each
tumor block, using a QIAamp DNA Mini kit (Qiagen,
Hilden, Germany). EGFR exons were amplified from the
DNA (100 ng) by polymerase chain reaction (PCR) in a
20-µL solution containing 2 µL of 10×buffer (Roche,
Mannheim, Germany), 1.7 to 2.5 mmol/L of MgCl2,
0.3 µM of each EGFR primer pair (exon 18, F: 5’-tccaaa
tgagctggcaagtg, R: 5’-tcccaaacactcagtgaaacaaa; exon 19, F: 5’-
atgtggcaccatctcacaattgcc, R: 5’-ccacacagcaaagcagaaactcac;
exon 20, F:5’-cattcatgcgtcttcacctg, R: 5’-catatccccatggcaaactc;
exon 21, F: 5’-gctcagagcctggcatgaa, R: 5’-cat cctcccctgcatgtgt),
250 µmol/L of deoxynucleotide triphosphates, and 2.5
units of DNA polymerase (Roche). Amplifications were
performed using a 5-min initial denaturation at 94˚C
followed by 30 cycles of 1 min at 94˚C , 1 min at 57˚C , and 1
min at 72˚C , with a final 10-min extension at 72˚C . KRAS
was similarly amplified from the DNA, except that a
primer pair for KRAS codons 12 and 13 was used (F: 5’-
ttatgtgtgacatgttctaat and R: 5’-agaatggtcctgcaccagtaa)
and the amplification conditions were a 5-min initial
denaturation at 94˚C ; 30 cycles of 1 min at 94˚C , and 1
min at 55˚C , 1 min at 72˚C ; and a final 10-min extension
at 72˚C . All PCR products were purified from a 2% agarose
gel, using a QIAgen gel extraction kit (Qiagen), and used
as templates for DNA sequencing with both forward and
reverse sequence-specific primers.
For sequencing, each purified PCR product (20 ng) was
used in a 20-µL sequencing reaction solution containing 8
µL of BigDye Terminator v3.1 (Applied Biosystems, Foster
City, CA) and 0.1 µmol/L of the appropriate PCR primers.
Sequencing was performed with 25 cycles of 10 s at 96˚C ,
5 s at 50˚C , and 4 min at 60˚C , using an ABI PRISM 3100
DNA Analyzer (Applied Biosystems). The data were
analyzed using Sequencer 3.1.1. software (Applied
Biosystems), to compare the sequence variations. 
Statistical analysis
The statistical analyses of categorical variables were
performed using Pearson’s χ
2 test or Fisher’s exact test, as
appropriate. The median duration for overall patient
survival was calculated using the Kaplan-Meier method.
Comparisons between groups were made using the log-
rank test. Multivariate analysis was carried out using the
stepwise Cox regression model. Two-sided p values <0.05
were considered significant. All analyses were performed
using SPSS for Windows, version 12.0 (SPSS Inc.,
Chicago, IL).
RESULTS
EGFR mutations in tumors
There were 104 patients (male, 56; female, 48), with a
mean age of 57.3 years (range, 30-76). Forty-six patients
were current or ex-smokers. The cancer stages of the
patients are shown in Table 1. Eighty-one (77.9%) patients
underwent surgery, 17 patients received chemotherapy
with or without radiotherapy, and six patients received
only supportive care.
A mutation of the EGFR gene was detected in 25 (24%)
of the 104 tumors: one mutation in exon 18 (G719S point
mutation); 13 in exon 19 (9-18 bp in- frame deletion); one
in exon 20 (M766L/P772L point mutation); and 10 in
exon 21 (L858R point mutation) (Fig. 1). There were no
tumors with multiple mutations. In exon 19, all 13 of the
mutations were small in-frame deletions of the kinase
domain; four were K745-A750del, two were E746-
A750del, four were E746-T753del, one was E746-P753del,
one was L747-S752, and one was L747-E749del. In exon
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second nucleotide of codon 858, resulting in the sub-
stitution of an arginine for a leucine in the protein. The
mutation in exon 18 was a substitution of A for G at
nucleotide 2155, producing a glycine instead of a serine at
codon 719. The mutation in exon 20 substituted G for A
and C for T at nucleotide 2298 and resulted in an amino
acid substitution of methionine for isoleucine at codon
766 and proline for leucine at codon 772.
The presence of EGFR mutations was not associated
with age, clinical stage, gender, smoking history, or
carcinoembryonic antigen (CEA) level. There was also no
correlation between EGFR mutations and the pathological
subtype or differentiation in these patients. However,
EGFR mutations were more frequently associated with a
high hemoglobin level (14.3 vs. 33.3%, <12 g/dL vs. ≥12
g/dL; p=0.042) (Table 2).
KRAS mutations were present in 9.6% [9] of 94 tumors
(8 mutations in codon 12 and 1 in codon 13). EGFR
mutations were never found in tumors with KRAS
mutations, suggesting a mutually exclusive relationship.
Correlation between mutations and survival time 
At the time of the analysis, 49 deaths (47.1%) had
occurred. The Kaplan-Meier curves indicated that the site
of the EGFR mutation did not affect patient prognosis
(median survival time: 775 days with exon 19 mutation vs.
824 days with exon 21 mutation; p=0.483), and smoking
history was not associated with survival outcome. The
survival time for patients with KRAS mutations tended to
be shorter than that for patients with EGFR mutations
(median survival time: 17.5 vs. 25.5 months), but the
difference was not statistically significant.
Table 3 shows the results of the univariate analysis.
Female patients had a longer median survival time than
male patients (p=0.0017), and patients with a higher CEA
serum level had a longer median survival time than the
other patients (p=0.0154). Patients with bronchi-
oloalveolar cell carcinoma and alveolar cell components
had a longer median survival time than other adeno-
carcinoma patients (p=0.0016). The median survival
time of the well-differentiated carcinoma patients was
longer than that of patients with moderate to poorly di-
fferentiated carcinoma (p=0.0546). According to the
univariate analysis, stage, CEA level, gender, smoking
history, pathological subtype, and differentiation were
the covariates selected for potential inclusion in a
multivariate Cox regression model of patient survival.
The selected model included stage (p=0.0000), gender
(p=0.027), pathological subtype (p=0.003), and
differentiation (p=0.024) (Table 4). 
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Figure 1. Mutations of the EGF receptor in lung cancer tissues.
Most of mutations were found at Exon 19 and Exon 21. Numbers
in parentheses indicated the number of lung cancer patients with
mutations.
Exon 18









Exon 20 Exon 21
Table 1.  Patient characteristics
Variable No.  (%)
Total 104
Gender 
Male 56  (53.8) 
Female 48  (46.2) 
Mean age (yr)  57.3±9.6* (30-76)
Smoking status 
Ever-smoker 46  (49.5) 
Non-smoker 47  (50.5)
Amount of smoking (packs/y) 29.7±12.8*
Stage
IA 10  (9.6) 
IB 30  (28.3)
IIB 6  (5.8)
IIB 8  (7.7)
IIIA 19  (18.3)
IIIB 16  (15.4)
IV 15  (14.2)
*Mean±SD (range) DISCUSSION
Adenocarcinoma is the most common histological
subtype of lung cancer, and its incidence is increasing in
Korea [8]. The frequency of EGFR mutations in non-small
cell lung cancer (NSCLC) has been reported to be 20-40%
in Asian patients. We found that 24% of 104 randomly
selected patients with lung adenocarcinoma carried
mutations in the TK domain of the EGFR gene, which is
consistent with previous reports [9-11]. Therefore, studies
have confirmed that the EGFR mutation is common in
Asian patients. Pao et al. [9] retrospectively examined 192
EGFR TK-domain mutations and found that 85.9% of
these were in one of two hot spots. Similarly, 92% of the
mutations in our study occurred in one of two hot spots.
It has been previously reported that EGFR mutations
are more frequent in female patients and in those who
have never smoked [7,12]. Shigematsu et al. [11] found
EGFR gene mutations to be more prevalent in females
than in males but independent of smoking status in
Japanese patients. Huang et al. [13] reported no sign-
ificant association between the presence of an EGFR
mutation and gender or smoking history in Chinese
patients. In the present study on Korean patients, EGFR
mutations were not associated with gender, smoking
history, age, histological grade, bronchioloalveolar com-
ponents, or tumor stage. Although Korea is geograph-
ically close to China and Japan, many cultural differences,
including smoking rate, nutrition, housing, and genetic
backgrounds, exist among the three populations and may
account for the different findings in these studies.
Furthermore, differences may exist among the studies
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Table 2. Relationship between EGFR mutations and clinical/pathological features in a subset of patients
Variable N  EFGR mutation, %  p value
Age (yr)
<60 57 26.5 0.549
≥60 47 21.3
Gender
Male 56 26.8 0.479
Female 48 20.8
Smoking status
Never 47 23.4 0.821
Ever 46 26.1
Packs per year
<30 19 31.6 0.477
≥30 27 22.2
Hemoglobin
<12 35 14.3 0.042
≥12 60 33.3
CEA (ng/mL)
<5 49 27.3 0.864
≥5 51 25.0
Stage
I-IIIA 73 24.7 0.821
IIIB-IV 31 22.6
Pathology
BAC 21 28.6 0.576
ADC 83 22.9
Grade
Well 26 26.9 0.22
>Moderate 26.9 23.1
KRAS
Mutated 9 0 0.000
Wild type 95  26.3
N, number; CEA, carcinoembryonic antigen; BAC, bronchioloalveolar carcinoma and adenocarcinoma with BAC component; ADC,
adenocarcinoma.related to selection bias due to heterogeneous pathological
profiles of patients [10].
It has been reported that EFGR mutations are detected
more frequently in younger patients and in those with
more advanced stages of lung cancer [9]. However,
Kosaka et al. [14] found no association between EGFR
mutations, age, and lung cancer stage. We also found that
EGFR mutations were not associated with disease stage,
suggesting that EGFR mutations occur relatively early in
the clinical course of adenocarcinoma and are associated
with its pathogenesis rather than its progression. EGFR
mutations may also be more common in tumors with
features of bronchioalveolar carcinoma (BAC) histology
[6,7,10]. However, based on the World Health Organization’s
classification criteria for lung tumors [15], we found no
association between EGFR mutation status and BAC or
the BAC subtype of adenocarcinoma. 
The reason for the marked difference in the response to
anti-EGFR agents between East Asian and American
patients is not clear. The geographical differences between
the populations may reflect differences in genetic
susceptibility. The first intron of the EGFR gene contains a
dinucleotide (CA) repeat [16], and the number of CA
repeats, which ranges from 14 to 21, correlates with the
transcriptional activity [17,18]. Given this association
between EGFR protein expression and the length of the
CA repeat polymorphism, genotypic background may
contribute to the variability in EGFR expression and thus
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Table 3. Univariate survival estimates for patients
Variable N MST (days)  95% CI (days)  p value
CEA 
<5 ng/mL 49 1,354 0.0154
≥5 ng/mL 51 1,027 222-1,831 
Gender 
Male 56 695 446-944 0.0017
Female 48 1,669 1,022-2,316
Smoking history
Never-smoker 47 1,126 577-1,675 0.316
Smoker 46 837 398-1,276
Pathology
BAC* 21 1,669 0.0016
Adenocarcinoma 83 711  548-874 
Differentiation
Well 26 1,354 1,121-1,586 0.0546
Moderate to poor  68 775  580-967
Mutation
KRAS 9 533 265-801 0.308
EGFR 25 775 622-928
Wild type 70 1,184 983-1,385
EGFR mutation
Exon 19 13 775  620-930 0.4829
Exon 21 10 824 622-1,025
N, number; MST, median survival time; CI, confidence interval. 
*Bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC component.
Table 4. Cox multivariate regression model of survival in lung cancer patients
Variable  Coefficient SE HR (95% CI)  p value
Stage 0.853 0.205 2.348 (1.57-3.51) 0.000
Gender -0.74 0.335 0.477 (0.25-0.92) 0.027
EGFR mutation 0.211 0.378 1.235 (0.59-2.59) 0.576
Pathology* 2.059 0.692 7.840 (2.02-30.4)  0.003
Differentiation
† -1.19 0.529 0.304 (0.11-0.86) 0.024
CEA 0.002 0.002 1.002 (0.99-1.00) 0.321
*Well differentiated versus moderate and poorly differentiated adenocarcinoma.
† Bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC component versus adenocarcinoma.to the differential response of patients to anti-EGFR
agents [16,17]. The polymorphism lengths in East Asians
are considerably longer than those in Caucasians and
African-Americans. Furthermore, the difference in the
incidence of non-smoking patients with lung cancer may
in part reflect these genetic differences. We found that
85% of female patients and 26% of male lung cancer
patients had never smoked. These percentages are much
lower in American lung cancer patients, with only 15% of
female and 6% of male patients with lung cancer in the
U.S. having never smoked, and there is a similar trend in
East Asia [18,19].
EGFR and KRAS mutations are mutually exclusive,
suggesting that they have functionally equivalent roles in
lung tumorigenesis [11,14]. Fifteen to 30% of lung
adenocarcinomas contain activating mutations in a KRAS
family member. These mutations occur most frequently in
codons 12 and 13 encoded in exon 2 [21,22] and may be
associated with unfavorable outcomes [23]. In the present
study, a KRAS mutation was detected in 9.6% of the
samples, which was a lower occurrence than that noted in
other reports [24]. However, the frequency of the KRAS
mutation among East Asian patients ranges from 8% to
13% of lung adenocarcinomas [10,14]. The high incidence
of EGFR mutations in East Asians with lung adeno-
carcinomas may explain the lower frequency of KRAS
mutations in East Asians compared with that in
Caucasian patients. KRAS mutations more frequently
occur in individuals with a history of substantial cigarette
use and are increasingly likely to be a function of higher
tobacco exposure [23]. Histological grade and cell type
may be prognostic factors. Multiple studies have reported
improved survival in never-smokers with primary
adenocarcinoma of the lung [25,26]. De Perrot et al. [27]
found that women were more likely to have never smoked
than men and that 54% of women had the NSCLC subtype
of adenocarcinoma. Furthermore, compared with men,
women had superior survival independent of age,
presence of symptoms, smoking habits, histology, or
disease stage. Therefore, lung cancer has a different
intrinsic biological behavior and natural history in women
compared with men. The 5-yr survival rate for women
with lung cancer was reported to be 17.3% compared with
13.8% for men [27]. 
In conclusion, we found a high prevalence of EGFR
mutations in Korean patients with adenocarcinoma of the
lung. EGFR mutations were never present in tumors that
had KRAS mutations, indicating the possible importance
of a genotypeoriented approach for diagnosis and treat-
ment of pulmonary adenocarcinoma. Our results did not
show a correlation between the presence of an EGFR
mutation and smoking history, gender, age, or disease
stage. 
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